Chronic itch: emerging treatments following new research concepts
- 31 August 2021
- journal article
- review article
- Published by Wiley in British Journal of Pharmacology
- Vol. 178 (24) , 4775-4791
Abstract
Until recently, itch pathophysiology was poorly understood and treatments were poorly effective in relieving itch. Current progress in our knowledge of the itch processing, the numerous mediators and receptors involved has led to a large variety of possible therapeutic pathways. Currently, inhibitors of IL‐31, IL‐4/13, NK1 receptors, opioids and cannabinoids, JAK, PDE4 or TRP are the main compounds involved in clinical trials. However, many new targets, such as Mas‐related GPCRs and unexpected new pathways need to be also explored.Keywords
This publication has 147 references indexed in Scilit:
- Emerging role of Toll-like receptors in the control of pain and itchNeuroscience Bulletin, 2012
- Unidirectional Cross-Activation of GRPR by MOR1D Uncouples Itch and Analgesia Induced by OpioidsCell, 2011
- TRPA1 is required for histamine-independent, Mas-related G protein–coupled receptor–mediated itchNature Neuroscience, 2011
- Regulated Proenkephalin Expression in Human Skin and Cultured Skin CellsJournal of Investigative Dermatology, 2011
- VGLUT2-Dependent Sensory Neurons in the TRPV1 Population Regulate Pain and ItchNeuron, 2010
- Toll-like receptor 7 mediates pruritusNature Neuroscience, 2010
- Cathepsin S Elicits Itch and Signals via Protease-Activated ReceptorsJournal of Investigative Dermatology, 2010
- Loss of Inhibitory Interneurons in the Dorsal Spinal Cord and Elevated Itch in Bhlhb5 Mutant MiceNeuron, 2010
- Sensory Neuron-Specific GPCR Mrgprs Are Itch Receptors Mediating Chloroquine-Induced PruritusCell, 2009
- TRPV1-expressing primary afferents generate behavioral responses to pruritogens via multiple mechanismsProceedings of the National Academy of Sciences, 2009